Discovery: A Peptide Hidden in the Mitochondrial Genome
MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA type-c) was first identified in 2015 by Lee et al. at the University of Southern California in a study published in Cell Metabolism — one of the most prestigious journals in metabolic science. The discovery was significant not merely for the peptide itself but for what it revealed about mitochondrial biology: that the mitochondrial genome, long thought to encode only 13 proteins involved in the electron transport chain, also encodes bioactive peptides with systemic signalling functions [1].
MOTS-c consists of 16 amino acids and is encoded within the 12S ribosomal RNA gene of the mitochondrial genome. Its identification opened a new field of research into mitochondria-derived peptides (MDPs) — a class of signalling molecules that communicate mitochondrial status to the rest of the cell and organism. Wan et al. (2023), reviewing the field in Frontiers in Pharmacology, describe MOTS-c as "mainly activated by stress and exercise, while its expression decreases with aging" — a pattern that positions it as a key mediator of the beneficial metabolic effects of physical activity [2].
Metabolic Homeostasis: The Landmark Cell Metabolism Study
The founding study by Lee et al. (2015) established the core metabolic profile of MOTS-c with a series of experiments that have since been cited over 826 times. The researchers demonstrated that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. The peptide achieved these effects by targeting skeletal muscle and activating the AMPK pathway — a central regulator of cellular energy homeostasis [1].
Mechanistically, MOTS-c was shown to promote glucose uptake in skeletal muscle independently of insulin signalling, suggesting a complementary pathway to conventional insulin-mediated glucose disposal. The peptide also activated the folate cycle and de novo purine biosynthesis, connecting mitochondrial function to one-carbon metabolism in a manner that had not previously been appreciated.
Exercise Mimetic Properties
Perhaps the most striking finding in MOTS-c research is its characterisation as an exercise mimetic — a compound that reproduces some of the metabolic adaptations induced by physical exercise without the exercise itself. Reynolds et al. (2021), publishing in Nature Communications and cited over 212 times, reported that mitochondrial-encoded MOTS-c can significantly enhance physical performance in young (2-month), middle-aged (12-month), and old (22-month) mice — demonstrating efficacy across the lifespan [3].
The exercise mimetic properties of MOTS-c are particularly relevant to ageing research. Circulating MOTS-c levels decline with age, mirroring the well-documented reduction in exercise capacity and metabolic flexibility that accompanies the ageing process. Kim et al. (2019), in Physiological Reports, demonstrated that MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity — effects that parallel those achieved through regular aerobic exercise [4].
Insulin Resistance and Type 2 Diabetes Research
The insulin-sensitising properties of MOTS-c have been investigated across multiple models of metabolic disease. Kong et al. (2023), publishing in the Diabetes & Metabolism Journal, reviewed the evidence for MOTS-c in the context of diabetes and ageing, concluding that it reduces insulin resistance by targeting skeletal muscle in mice fed a high-fat diet — a finding that has been cited over 23 times and is consistent across multiple independent research groups [5].
Yin et al. (2022), in a study published in Pharmacological Research, demonstrated that MOTS-c can be an effective treatment for gestational diabetes mellitus in preclinical models, reducing hyperglycaemia and improving insulin sensitivity through its effects on skeletal muscle glucose metabolism — a study cited over 70 times [6]. More recently, Pham et al. (2025), publishing in Frontiers in Physiology, demonstrated that MOTS-c restores mitochondrial respiration in the type 2 diabetic heart, suggesting cardioprotective applications beyond its established metabolic effects [7].
Longevity and Centenarian Studies
The association between MOTS-c and longevity has been investigated through both animal studies and human epidemiological research. Alser et al. (2022), in a study published in PLOS ONE, found that MOTS-c levels are associated with longevity in centenarians — individuals who have lived to 100 years or beyond. This finding suggests that maintaining MOTS-c signalling may be a feature of successful ageing, consistent with the peptide's role in preserving metabolic function and insulin sensitivity throughout the lifespan [8].
Mohtashami et al. (2022), reviewing MOTS-c in Frontiers in Physiology, summarised evidence for beneficial effects on age-related diseases including diabetes, cardiovascular disease, osteoporosis, and postmenopausal obesity — a breadth of application that reflects the peptide's fundamental role in mitochondrial-nuclear communication and whole-body metabolic regulation [9].
Muscle Biology and Sarcopenia Research
MOTS-c's effects on skeletal muscle extend beyond insulin sensitivity to include direct effects on muscle biology relevant to sarcopenia — the age-related loss of muscle mass and function. Research published in the American Journal of Physiology — Endocrinology and Metabolism demonstrated that MOTS-c reduces myostatin and muscle atrophy signalling, suggesting a potential role in preserving muscle mass during ageing or disease-related muscle wasting.
Research Purity and Handling
MOTS-c is a 16-amino acid peptide with a molecular weight of approximately 2,174 Da. Its relatively small size facilitates synthesis, but the peptide requires careful handling to maintain biological activity. Research-grade MOTS-c should be verified by HPLC to a minimum purity of 98%, with mass spectrometry confirmation of the correct molecular weight. The peptide is typically reconstituted in sterile bacteriostatic water or phosphate-buffered saline for research applications.
Conclusion
MOTS-c represents a paradigm shift in our understanding of mitochondrial biology and metabolic signalling. Its discovery revealed that the mitochondrial genome encodes bioactive peptides with systemic effects, opening an entirely new field of research. The evidence base — spanning over 826 citations for the foundational Cell Metabolism study alone — establishes MOTS-c as one of the most rigorously investigated metabolic peptides in contemporary science. Its exercise mimetic properties, insulin-sensitising effects, and associations with longevity in centenarians make it a compelling subject for continued research into metabolic health and healthy ageing.
References
- [1] Lee C et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism (2015). DOI: 10.1016/j.cmet.2015.02.009.View Source
- [2] Wan W et al. "Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging." Frontiers in Pharmacology (2023). DOI: 10.3389/fphar.2022.1083060.View Source
- [3] Reynolds JC et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications (2021). DOI: 10.1038/s41467-021-20870-z.View Source
- [4] Kim SJ et al. "The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity." Physiological Reports (2019). DOI: 10.14814/phy2.14171.View Source
- [5] Kong BS et al. "Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging." Diabetes & Metabolism Journal (2023). DOI: 10.4093/dmj.2022.0333.View Source
- [6] Yin Y et al. "The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus." Pharmacological Research (2022). DOI: 10.1016/j.phrs.2021.106006.View Source
- [7] Pham T et al. "Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart." Frontiers in Physiology (2025). DOI: 10.3389/fphys.2025.1602271.View Source
- [8] Alser M et al. "The Effect of Chronic Endurance Exercise on Serum Levels of MOTS-c and its Association with Longevity in Centenarians." PLOS ONE (2022). DOI: 10.1371/journal.pone.0271874.View Source
- [9] Mohtashami Z et al. "MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Its Role in Clinical Diseases." Frontiers in Aging (2022). DOI: 10.3389/fragi.2022.1008740.View Source
Bionexis Research Team
Peptide Science & Quality Assurance Division
The Bionexis Research Team reviews and synthesises published scientific literature to provide accurate, evidence-based information for the peptide research community. All articles undergo editorial review to ensure factual accuracy and proper citation of peer-reviewed sources.
Research Use Disclaimer: This article is provided for informational and educational purposes only. All peptides referenced are intended for laboratory research use only and are not intended for human consumption. The information presented is based on published scientific studies and does not constitute medical advice. Always consult qualified professionals for health-related decisions.